Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Breast Neoplasms 17Carcinoma, Renal Cell 14Neoplasms 12Neoplasm Metastasis 9Neuroendocrine Tumors 7Head and Neck Neoplasms 7Kidney Neoplasms 6Pancreatic Neoplasms 5Prostatic Neoplasms 4Lung Neoplasms 4Squamous Cell Carcinoma of Head and Neck 3Recurrence 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma 3Leukemia, Lymphocytic, Chronic, B-Cell 3Carcinoma, Non-Small-Cell Lung 3Carcinoma, Hepatocellular 3Waldenstrom Macroglobulinemia 2Urinary Bladder Neoplasms 2Triple Negative Breast Neoplasms 2Somatostatinoma 2Pheochromocytoma 2Paraganglioma 2Neuroectodermal Tumors, Primitive 2Lymphoma, T-Cell, Cutaneous 2Lymphoma, Non-Hodgkin 2Lymphoma, Mantle-Cell 2Lymphoma, Follicular 2Insulinoma 2Hodgkin Disease 2

Interventions

ofatumumab 3Vincristine 2Rituximab 2Lenalidomide 2Bortezomib 2tenofovir alafenamide 1pomalidomide 1pivalyloxymethyl butyrate 1pegaspargase 1nelarabine 1immunotoxin HA22 1fludarabine 1bempegaldesleukin 1Whole-Body Irradiation 1Tablets 1Panobinostat 1Observation 1Nivolumab 1Mitoxantrone 1Methotrexate 1Mercaptopurine 1Everolimus 1Etoposide 1Drug Therapy 1Dexamethasone 1DTRMWXHS-12 1Cytarabine 1Cyclophosphamide 1Clofarabine 1Cladribine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leukemia, B-Cell × Everolimus × Clear all
NCT04305444 2025-01-08

Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas

Zhejiang DTRM Biopharma

Phase 2 Terminated
55 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphatic Diseases, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Neoplasms, Leukemia, B-Cell, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse

Data powered by HemOnc (CC BY 4.0) Colophon âš¡